The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Dermalogica’s PRO Pen Microneedling System, designating it a Class II medical device, as confirmed by the Chief Executive Officer at Dermalogica, Aurelian Lis. The clearance restricts use to licensed physicians and professional skin care therapists, underscoring the brand’s commitment to science-backed treatments.
FDA clearance is rare in the skincare category, where most products rely on marketing claims rather than rigorous clinical validation. To earn the designation, devices must demonstrate safety, efficacy, and compliance with strict regulatory standards—requirements that set a higher bar for the industry.
The PRO Pen represents the next evolution in Dermalogica’s professional heritage. For decades, the company has invested in education-driven innovation to elevate skin health treatments in clinical and spa settings. By aligning advanced technology with trained professionals, the brand signals where the future of skincare is heading: outcomes driven by measurable results rather than hype.
This milestone also raises a wider industry question: as consumer devices proliferate, will the line between professional and at-home treatments continue to blur—or will FDA-cleared technologies like the PRO Pen reinforce the distinct role of trained experts in delivering results?
